MK 0941

Drug Profile

MK 0941

Alternative Names: MK-0941

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 24 Sep 2010 Efficacy and safety data from three phase II trials in Type-2 diabetes mellitus presented at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD-2010)
  • 24 Feb 2010 Merck completes two multinational phase II trials (NCT00824616 and NCT00792935) in Type-2 diabetes mellitus
  • 17 Nov 2008 Phase-II clinical trials in Type-2 diabetes mellitus in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top